

References

1. https://en.wikipedia.org/wiki/Opportunity_cost
2. Restoring the pharmaceutical industry's reputation. *Nature Biotechnology* (Commentary). URL: <http://www.nature.com/nbt/journal/v32/n10/full/nbt.3036.html>
3. Conflict of Interest in Medical research, Education, and Practice. The National Academies. URL: <https://www.ncbi.nlm.nih.gov/books/NBK22926/>
4. John Manoogian III, Buster Benson, Wikipedians. *Cognitive Bias Codex 2016*. URL: https://d262ilb51hltx0.cloudfront.net/max/2000/1*71TzKnr7bzXU_1_pU6DCNA.jpg
5. Yavchitz et al. A new classification of spin in systematic reviews and meta-analysis was developed and ranked according to severity. *J Clin Epidemiol*. 2016 Jul;75:56-65. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26845744>
6. Bekelman, Li & Gross. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA* 2003 Jan 22-29;289(4):454-65. URL: <https://www.ncbi.nlm.nih.gov/pubmed/12533125>
7. Yeh et al. Association of industry payments to physicians with the prescribing brand-name statins in Massachusetts. *JAMA Intern Med*. 2016 Jun 1;176(6):763-8. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27159336>
8. Othman et al. Quality of pharmaceutical advertisements in medical journals: a systematic review. *Plos One* 2009 Jul 22;4(7):e6350. URL: <https://www.ncbi.nlm.nih.gov/pubmed/19623259>
Institute of Medicine. *Clinical Practice Guidelines We Can Trust*. URL: <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0079466/#ddd00083> (Indirect reference)